Compare EPSN & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | RNAC |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 218.4M |
| IPO Year | 2018 | 2016 |
| Metric | EPSN | RNAC |
|---|---|---|
| Price | $4.96 | $5.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $33.67 |
| AVG Volume (30 Days) | 62.5K | ★ 110.5K |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $274.53 |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.20 | $5.60 |
| 52 Week High | $6.65 | $11.00 |
| Indicator | EPSN | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 27.46 | 38.17 |
| Support Level | N/A | $5.90 |
| Resistance Level | $5.12 | $7.64 |
| Average True Range (ATR) | 0.28 | 0.52 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 2.76 | 4.75 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.